Shares of Milestone Therapeutics MIST fell 21.67% during market hours on Oct 17, after rising 41% in premarket, post the company’s announcement of top-line results from a late-stage study evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback